retatrutide phase 2 trial results obesity VisualAbstract: reduces body weight by 17.5% in patients with Retatrutide (LY3437943), a Novel GIP/GLP-1/Glucagon

The National Family Health Survey (NFHS-4, 2015-16) reported that 20.7% of women and 18.6% of men in the 15-49 age group were overweight or obese, underscoring the urgent need for effective weight-loss solutions

Chng nng ni sinh bo v da khi tia UV: Chit xut dng x Polypodium Leucotomos gip gim tc hi ca tia UV, hn ch chy nng v sm da

Direct-to-employer (DTE) access models better forecast drug spending, improve pricing transparency, and reduce administrative complexity, allowing employers to focus on outcomes rather than operational burden

These vasodilatory mechanisms are diverse but share two distinct characteristics in that the activity of each of the differing mechanisms increases in direct response to increasing intensities of exercise and those mechanisms all initiate the synthesis of nitric oxide (NO)

Meanwhile, Novo Nordisk sells a weight-loss specific version called Wegovy for obesity treatment